University of Texas Southwestern Medical Center (UT Southwestern)

Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Final analysis results from the phase 3 KEYNOTE-522 study. (2026) Schmid P, Cortes J, Dent RA, McArthur HL, Pusztai L, Kuemmel S, Denkert C, et al. Journal article Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial. Diabetes Care 2026;49:257–265 (2026) Mann JF, Jeppesen OK, Belmar N, McGuire DK, Buse JB Journal article Safety of Semaglutide After Dialysis Initiation: An Individual-Level Pooled Analysis (2026) Klein KR, Menacher A, Buse JB, Mann J, Tuttle KR, Kvist K, Andersen MR, et al. Journal article Effect of Oral Semaglutide on Cardiovascular Outcomes in Type 2 Diabetes by Extent of Vascular Disease (2026) Cavender MA, Marx N, Mulvagh SL, Deanfield JE, Buse JB, Inzucchi SE, Pop-Busui R, et al. Journal article ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer-Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study (2026) Kuemmel S, Fasching P, Schmid P, Harbeck N, Takahashi M, Untch M, Boileau JF, et al. Journal article Immune checkpoint inhibitor-associated myocarditis: A novel risk score (2026) Power JR, Dolladille C, Ozbay B, Procureur A, Ederhy S, Palaskas NL, Lehmann LH, et al. Journal article Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial (2026) Mann JF, Marx N, Deanfield JE, Emerson SS, Inzucchi SE, McGuire DK, Mulvagh SL, et al. Journal article International Society of Urological Pathology Multidisciplinary Expert Consultation Conference on Evaluation of Treatment Effects in Prostate and Bladder Cancer: Working Group 2: The Urinary Bladder (2026) Downes MR, Wobker SE, Smith SC, Eckstein M, Akgul M, Baydar DE, Brimo F, et al. Journal article Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model. (2026) Lachowiez CA, Zeidner JF, Othman J, Kaempf A, Yun S, Heiblig M, Heuser M, et al. Journal article Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals (2026) Neuen BL, Major RW, Grams ME, Sang Y, Coresh J, Ballew SH, Surapaneni A, et al. Journal article